![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 25, 2024
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2024 Group Meeting
November 25, 2024
EA5162 is testing a new therapy for certain patients with advanced NSCLC who have developed resistance to other treatments
November 25, 2024
October 17, 2024
The co-chairs reflect on how the cancer research landscape has evolved over the last five years
October 17, 2024
In August, the cancer research community lost a leader in the fields of breast cancer and surgical oncology
October 17, 2024
The Patient-Reported Outcomes (PRO) Advisory Group guides study investigators on how best to include PRO measures and endpoints in clinical trials
October 17, 2024
The Journal of Clinical Oncology has published a proposal to jump-start correlative research, which is almost at a standstill
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
October 17, 2024
Summaries of recently published ECOG-ACRIN research results
October 17, 2024
August 22, 2024
This phase 3 study is comparing BRAF-targeted therapy with dabrafenib-trametinib to TKI therapy with cabozantinib in patients with disease progression following standard treatments
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012